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Specific N-glycans of 
Hepatocellular Carcinoma Cell 
Surface and the Abnormal Increase 
of Core-α-1, 6-fucosylated 
Triantennary Glycan via 
N-acetylglucosaminyltransferases-
IVa Regulation
Huan Nie1,*, Xia Liu1,4,*, Yubao Zhang3,*, Tingting Li1, Chao Zhan3, Wenjuan Huo1, 
Anshun He1, Yuanfei Yao1, Yu Jin3, Youpeng Qu1, Xue-Long Sun2 & Yu Li1
Glycosylation alterations of cell surface proteins are often observed during the progression of 
malignancies. The specific cell surface N-glycans were profiled in hepatocellular carcinoma (HCC) 
with clinical tissues (88 tumor and adjacent normal tissues) and the corresponding serum samples 
of HCC patients. The level of core-α-1,6-fucosylated triantennary glycan (NA3Fb) increased both 
on the cell surface and in the serum samples of HCC patients (p < 0.01). Additionally, the change 
of NA3Fb was not influenced by Hepatitis B virus (HBV)and cirrhosis. Furthermore, the mRNA and 
protein expression of N-acetylglucosaminyltransferase IVa (GnT-IVa), which was related to the 
synthesis of the NA3Fb, was substantially increased in HCC tissues. Knockdown of GnT-IVa leads 
to a decreased level of NA3Fb and decreased ability of invasion and migration in HCC cells. NA3Fb 
can be regarded as a specific cell surface N-glycan of HCC. The high expression of GnT-IVa is the 
cause of the abnormal increase of NA3Fb on the HCC cell surface, which regulates cell migration. 
This study demonstrated the specific N-glycans of the cell surface and the mechanisms of altered 
glycoform related with HCC. These findings lead to better understanding of the function of glycan 
and glycosyltransferase in the tumorigenesis, progression and metastasis of HCC.
The liver is an active secretory organ and is one of the organs of the secretory glycoproteins. Hepatocellular 
carcinoma (HCC) is one of the most common cancers and has very high mortality due to its difficult 
early diagnosis and limited treatment. HCC was responsible for approximately 748,300 new liver cancer 
cases and 695,900 cancer mortalities worldwide in 2008, ranking as the second most frequent cause of 
cancer death1. Half of these cases and deaths were estimated to occur in China. However, HCC inci-
dence rates are increasing in many parts of the world, including the United States and Central Europe2. 
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Therefore, it is urgent to study the molecular mechanism of HCC and to find therapeutic targets and 
diagnosis mechanisms for effective medical treatment.
Cell surface glycans play an important role in intercellular and intracellular processes, including cell 
adhesion and development, cell recognition, and cancer development and metastasis3. Changes in cell 
surface glycosylation modulate cellular activity. Aberrant glycosylation of the cellsurface is associated 
with the malignant transformation of normal cells. Tumor-cell-surface glycans are closely associated 
with tumor-cell migration, adhesion, and metastasis4. The tumor cells, through the cell-surface glycans, 
can bind to the glycan-binding receptors - lectins on endothelial cells and immune cells - and thereby 
affect tumor-cell progression5. As an attractive and widely pursued field, this research has attempted to 
find cancer biomarkers or drug targets in cancer-specific, cell-surface glycans. The majority of studies 
of glycosylation changes in HCC are conducted using patient serum samples6. Few studies have focused 
on the altered mechanism of the glycoform in tissue samples. Dall'Olio et al. demonstrated the dramatic 
variations of the ST6GAL1 and α 2,6-sialylated glycoconjugates when the neoplastic transformation of 
hepatocytes occurred in 21 HCC cases7. Mehta et al. found that the tetra-antennary N-linked glycans 
changed by comparing 16 tumor samples and adjacent tissue8.
DNA sequencer-assisted fluorophore-assisted carbohydrate electrophoresis (DSA-FACE), which was 
developed by Callewaert, has been used to study the profile of serum as a robust, high-throughput, 
exceedingly sensitive, and reliable quantitative method9,10. Recently, we utilized this high-throughput 
glycomics method to profile cell surface-specific N-glycans from human breast cancer cell lines and 
tissues11. In this study, we analyzed 88 pairs of clinical tumor and adjacent tissues and 61 serum samples 
from 88 HCC patients using this N-glycomics procedure. The results revealed that NA3Fb was highly 
expressed on the cell surface of HCC cells (p < 0.01) and was increased in corresponding HCC patients’ 
serum samples (p < 0.01). Further, we found that the high expression of N-acetylglucosaminyltransferase 
IVa (GnT-IVa) caused an abnormal increase of NA3Fb on the HCC cell surface. Knockdown of GnT-IVa 
can lead to potent inhibition of the invasion and migration of HCC cells. This study revealed significant 
connections between altered N-glycans and the tumorigenesis, progression and metastasis of HCC, indi-
cating GnT-IVa as a therapeutic target for HCC treatment.
Results
The profiles and structures of the cell-surface N-glycan of HCC. DSA-FACE has been proved 
as a high-throughput tool to analyze cell-surface glycans. We used DSA-FACE to study the profiles 
and structures of the cell-surface N-glycans of HCC. To determine the structures of the cell-surface 
N-glycans, we compared their N-glycan profiles with that of RNaseB and HCC serum, whose N-glycan 
profiles were already known (Fig. 1). Exoglycosidase digestion was used to analyze the structure of the 
N-glycan pool (Supplementary Figure S1) as Nico Callewaert described in Nature Medicine9. We assigned 
the peaks L1 (M7), L2 (NA2), L3 (M8), L4 (M9+ NA2F), L5 (NA3) and L6 (NA3Fb) in the cell-surface 
N-glycan profiles.
Analysis of the HCC-specific cell-surface N-glycans. In this study, HCC clinical tissues (tumor and 
adjacent normal tissues, n = 88) were used to study the HCC-specific, cell-surface N-glycans (Table 1). 
Specimens were characterized according to the patients’ gender, age, tumor grade according to TNM 
stages and differentiation.
Paired and unpaired t-tests were used to compare normal and malignant tissues, and the intra- and 
inter-assay coefficients of variations (CVs) of the glycan analysis were less than 5%. The results showed 
that the N-glycan profiles of hepatocellular carcinoma tissues were substantially distinguished from those 
of the corresponding adjacent tissues (Fig. 2A). The levels of peaks L2 (NA2), L5 (NA3) and L6 (NA3Fb) 
were significantly increased in the tumor group (p < 0.01), but peak L3 (M8) was significantly decreased 
in the tumor group (p < 0.01) compared to the adjacent normal tissue group (Fig. 2B).
Because HCC patients often have viral infectionsand cirrhosis, we further analyzed the relation among 
the virus, the degree of cirrhosis and the level of these glycans. The results showed that the M8 and 
NA3Fb have the same tendency between HBV and non HBV patients. NA2 and NA3 were only altered 
in the group of HCC tissues infected with HBV (Fig. 2C). In addition, based on the degree of cirrhosis, 
the adjacent tissues were divided into three groups: normal (non-cirrhosis or cirrhosis area < 5%), cir-
rhosisI (5%< cirrhosis area < 30%) and cirrhosisII (cirrhosis > 30%) for glycan analysis after HE staining 
and pathological analysis of the frozen tissue section. Typical images of the three groups are shown in 
Supplementary Figure S2. The results revealed that the level of NA2, NA3 and NA3Fb decreased along 
with cirrhosis and were increased in HCC (Fig. 2D), which indicated that NA2, NA3 and NA3Fb were 
not influenced by cirrhosis. The level of M8 decreased with the increased degree of cirrhosis, and its level 
was the lowest in HCC. Therefore, NA3Fb can be regarded as a specific glycan on the surface of HCC.
The concentrations of a biantennary glycan (NA2), triantennary glycans (NA3 and NA3Fb) and a 
high-mannose glycan (M8) in hepatocellular carcinoma patients with different gender, age, clinical stage 
and tumor differentiation degree were compared to study the correlation between these N-glycans and 
the clinical characteristics. Peak L6 (NA3Fb) was significantly different in male and female patients, with 
age < = 50 and age >50 and in different TNM stage groups (Supplementary Figure S3) (p < 0.01). Based 
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on this observation, we speculated that peak L6 (NA3Fb) is associated with the malignant progression 
of hepatocellular carcinoma.
The change of NA3Fb in serum. Based on the results of the specific cell-surface glycan of HCC 
tissue, we continued to study the changes of NA3Fb in serum. The serum specimens of 61 from 88 HCC 
patients (Supplementary Table S3),along with 90 age- and gender-matched healthy humans as a control 
group, were analyzed using DSA-FACE. The results showed that the NA3Fb tendency is the same in 
clinical tissues and serum. The level of NA3Fb was significantly increased in the tumor group (p < 0.01) 
in serum (Fig. 3A). In addition, the level of NA3Fb was also increased in different age groups, indicating 
that it is age-independent (Fig.  3B). We analyzed only TNM-I stage patients in this study. The serum 
result was consistent with the clinic tissue, showing that the level of NA3Fb was higher in cancer group 
than in the control group (Fig. 3C), which further proved that the higher level of NA3Fb is caused by 
the changes of the synthetic pathway and has close relation with HCC.
The increase of NA3Fb in the cell surface accompanied by the high expression of 
GnT-IVa. After revealing the increase of NA3Fb in HCC clinical tissue and serum, we attempted to 
Figure 1. Cell surface N-glycan profiles of cell line and tissue of HCC based on DSA-FACE. (A) 
Oligomaltose is used as a sugar mass reference. The number of glucose units (degree of polymerization, DP) 
in these structures is indicated. (B) N-glycan profiles from RNaseB used as N-glycan profile controls. (C) 
HCC serum contained various complex N-glycans and the most abundant glycans detected in serum are 
marked. (D) and (E) are N-glycan profiles of cell surface of two HCC cell line, HepG2 and BEL-7402. (F) 
and (G) are N-glycan profiles of cell surface of HCC clinical tissues and adjacent normal tissues. NGA2F 
is an agalacto core-α -1, 6-fucosylated biantennary glycan; NA2 is a bigalacto biantennary glycan; NA2F 
is a bigalacto core-α -1, 6-fucosylated biantennary glycan; NA2FB is a bigalacto core-α -1, 6-fucosylated 
bisecting biantennary glycan; NA3 is tri-antennary; NA3Fb is a core-α -1, 6-fucosylated triantennary glycan. 
The symbols used in the structural formulas are as follows: (○ ) β -linked N-acetylglucosamine; (● ) β -linked 
galactose; (□ ) α -linked mannose; (■) β -linked mannose; (▲ ) α -1, 6-linked fucose.
www.nature.com/scientificreports/
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further investigate the related molecular mechanism. Because these glycan structures are synthesized by 
a series of glycosyltransferases, the transcriptional expression levels of 5 glycosyltransferases related with 
NA3Fb were studied,including FUT8 (fucosyltransferase 8, Fut8), GALT-1(galactose-1-phosphate uridy-
lyltransferase, GalT-1), MGAT5 (N-acetylglucosaminyltransferase V, GnT-V), MGAT4A and MGAT4B 
(N-acetylglucosaminyltransferase IVa and IVb, GnT-IVa and GnT-IVb). Thirty-four pairs of HCC tissue 
and adjacent normal tissue were used to study the 5 gene expressions by qRT-PCR. Among the 5 glycos-
yltransferases, only GnT-IVa expression was substantially increased in HCC tissues based on the pairwise 
comparison between individual HCC and paired adjacent normal tissue (p < 0.01) (Fig. 4A); the results 
of the other 4 glycosyltransferases are shown in Supplementary Figure S4.
To confirm the results of the qRT-PCR, the protein expression of GnT-IVa was evaluated in 16 HCC 
tissues and their adjacent normal tissue (Fig. 4B). The results showed that in 13 of 16 cases, the expres-
sion of GnT-IVa was increased in HCC tissues compared to the adjacent normal tissue, whereas in the 
other 3 cases, the expression level was similar in both tissues. These protein expression results are con-
sistent with those of the transcriptional expression. Collectively, these findings indicated that the high 
expression of GnT-IVa has close relation with the high level of NA3Fb.
Subsequently, GnT-IVa was knocked down in HepG2 cells by transfection with GnT-IVa shRNA 
(Fig.  5A,B). The results revealed that the level of NA3Fb decreased and M8 increased in knockdown 
GnT-IVa/1668 cells compared with GnT-IVa/NC after 48 h transfection (Fig. 5C,D). In addition, analysis 
of cell scratch healing and transwell migration in vitro was used to study the alteration of cell migration. 
The healing due to cell migration of HepG2 was observed over periods of 6 h and 48 h following scratch 
wounding (Fig.  6A). The quantitative data showed that the healing rates of the GnT-IVa/1668 group 
decreased more than the GnT-IVa/NC group (Fig. 6B). HepG2/1668, and HepG2/NC cells were seeded 
into the upper chamber of a transwell insert(Fig. 6C). The transwell migration and invasion test indicated 
that the number of cells invading the transwell of GnT-IVa/1668 was substantially reduced in comparison 
with GnT-IVa/NC (Fig. 6D). Similar results were obtained in another HCC cell line-BEL-7402(Supple-
mentary Figure S5).
These results proved that the high expression of GnT-IVa leads to a higher level of NA3Fb in the 
HCC cell surface, and the downregulation of GnT-IVa may modulatecell invasion and migration through 
NA3Fb.
Characteristics Category Cases Percentage (%)
Paired tissues 
(n = 88)
Gender
Male 73 83.0
Female 15 17.0
TNM stage
I 68 77.3
II 9 10.2
IIIa 5 5.7
III b 1 1.1
ND 5 5.7
Grade of differentiation
G1 4 4.5
G2 16 18.2
G3 31 35.2
ND 37 42.1
Degree of cirrhosis
< 5% 34 38.6
5%–30% 19 21.6
> 30% 9 10.3
ND 26 29.5
Virus
virus 80 90.9
Non-virus 8 9.1
Age
< 40 7 8.0
41–50 30 34.0
51–60 38 43.2
> 60 13 14.8
Table 1. Clinical Characteristics of the Study Populationa Located on page 7. aND, not determined; G1, 
high grade; G2, moderate grade; G3, poor grade.
www.nature.com/scientificreports/
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Figure 2. The significantly changed N-glycans in hepatocellular carcinoma tissues compared to adjacent 
normal tissues. (A) The typical cell surface-specific N-glycan profiles from hepatocellular carcinoma tissue 
and adjacent normal tissue. (B) The statistically significant differences of N-glycan peaks NA2, NA3, NA3Fb 
and M8 between cancer and adjacent normal tissues. (C) The relation between the degree of cirrhosis and 
the expression of NA2, NA3, NA3Fb and M8.
Figure 3. Analysis of the alternation of NA3Fb in the serum and tumor cells of same patient. The 
changes of NA3Fb in clinical tissues and serum of 61 HCC patients (A), different ages (B) and at TNM-I 
stage (C).
www.nature.com/scientificreports/
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Discussion
As the third biomacromolecules, glycans are becoming increasingly important in biological, chemical 
and clinical research and applications. Abnormal changes of glycans in both structures and amounts are 
closely related to many diseases. Altered glycosylation  is a universal feature of many types of cancers, 
including HCC12. However, more studies focus on serum and serum biomarkers.
DNA sequencer-assisted fluorophore-assisted carbohydrate electrophoresis (DSA-FACE) is a use-
ful high-throughput method for N-glycome profiling. This technique has been successfully applied 
for screening serum glycoprotein biomarkers from healthy people13,14, patients suffering various dis-
eases15–19 and cancer patients20–27. Our group previously studied the relation of serum glycan and aging 
using DSA-FACE28. Recently, we modified the DSA-FACE technique and used it to profile the cell 
surface-specific N-glycans in breast cancer11. In this study, we used DSA-FACE to analyze the N-linked 
glycan profiles of clinical HCC patient tissue and serum to identify the specific N-glycans of the cell 
surface in HCC and the molecular mechanism of their biosynthesis.
In our study, the profiles of the cell-surface N-glycans of HCC and 6 typical glycan structures were 
revealed. NA2 and NA3 were significantly increased in the tumor group compared to the adjacent normal 
tissue group. NA2 is a bigalacto-biantennary and NA3 is a tri-antennary glycan. Several previous studies 
Figure 4. The expression of MGAT4A correlation with the structure of NA3Fb. (A) The 
relative expressions of MGAT4A was determined by RT-PCR from 34 pairs of HCC and adjacent normal 
tissues. Statistical analysis was performed comparing HCCs with normal surrounding tissues. (B) Western 
blot analysis of GnT-IVa expression in 16 pairs of HCC and adjacent normal tissues. The results were 
normalized to the amount of GAPDH. *means P < 0.05.
www.nature.com/scientificreports/
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showed NA2 and NA3 as serum markers in different diseases of the liver. Goldman et al. found that 
the NA2 was less abundant in hepatocellular cancer (HCC) patients with hepatitis C virus (HCV) than 
in healthy humans12. Chen et al. found that NA2 was lower in a nonalcoholic steatohepatitis (NASH) 
group than in simple fatty liver (NAFL) and control groups17. Callewaert et al. found that during liver 
fibrosis progression, the amount of NA3 concentration decreases in the  serum N-glycome18. Gui et al. 
showed that the biantennary (NA2) and the triantennary (NA3) N-glycans decreased significantly with 
increased severity of fibrosis19. These results showed that NA2 and NA3 in serum were decreased in 
more serious stages of liver disease, which is similar to our results showing that NA2 and NA3 decreased 
in 61 HCC serum samples (Supplementary Figure S6). However, our results showed that the levels of 
NA2 and NA3 were increased in HCC tissues compared to adjacent normal tissue in the virus group. 
There is an opposite variation tendency of NA2 and NA3 inthe serum and tumor tissue of the same 
patientdue to the different secreting pathways of secreted and resident glycoproteins. The abundance 
of NA2 and NA3 in HCC tissue with virus indicates that they can be used as therapeutic targets for 
cancer treatment. Riproximin, a new type II ribosome-inactivating protein with antineoplastic activ-
ity from Ximenia americana, preferentially binds to the branched bi- and triantennary N-glycan struc-
tures NA2 and NA329, which may help riproximin to recognize the glycans in cancer cells, resulting in 
tumor-specific cytotoxicity.
In addition, the level of NA3Fb, a core-α -1, 6-fucosylated triantennary glycan, increased not only 
on the cell surface of HCC cells but also in corresponding HCC patients’ serum samples. The abnormal 
increase of NA3Fb appeared at the early HCC stages and was independent of patients’ age. Nakagawa 
demonstrated that this glycan was increased in α -fetoproteins (AFPs) from HCC by detecting the 
N-glycan structures of AFPs from cell lines, serum and ascites fluids from HCC patients30. A similar 
core, fucosylated, tri-antennary glycan with sialic acid, G2890, was increased in the serum of the HCC 
group and was viewed as a promising biomarker for malignant behavior in HCCs31. Our previous studies 
showed that this glycan was increased in breast cancer serum and tissue11. Cancer cells frequently dis-
play glycans at different levels or with fundamentally different structures than those observed in normal 
cells32. The glycans have been proven to be in direct relation with cancer oncogenesis, and some have 
been regarded as tumor-associated antigens, such as mucin-related Tn, Sialyl Tn, and the blood group 
Lewis-related Lewis Y and Sialyl Lewis X33. Therefore, the alteration of the core-α -1, 6-fucosylated triant-
ennary glycan in the serum and tissue of breast cancer and HCC may reflect the change of the molecular 
mechanism in cancer oncogenesis and may serve as a new tumor-associated antigen or drug target.
Figure 5. The relative quantity of HepG2 cell surface NA3Fb at 48 h after the transfection of GnT-IVa. 
(A) qRT-PCR and (B) Western blot analysis of GnT-IVa expression. (C) The DSA-FACE figure of the cell 
surface glycan. (D) The normalization results of intensity of NA3Fb and M8.
www.nature.com/scientificreports/
8Scientific RepoRts | 5:16007 | DOi: 10.1038/srep16007
Glycosylation is controlled by both glycosyltransferases and glycosidases and responds to the cellular 
microenvironment as a result of cellular responses34. The biosynthesis of complex N-glycans is cata-
lyzed by the action of N-acetylglucosaminyltransferases (GnTs) in the medial-Golgi apparatus, which 
adds antennae branching structures to the common core structure. GnT-IV and GnT-V are required 
for the formation of tri- and multiantennary branching structures on membrane proteins that require 
glycosylation as a signal for exportation in the Golgi apparatus35. Therefore, GnT-IV may have func-
tional roles that are no less important than those of GnT-V. GnT-IVa and GnT-IVb isoenzymes have 
GnT-IV enzymatic activity and share substrate specificity with different tissue distribution profiles36. In 
this study, we further investigated the molecular mechanism of the considerable increase of NA3Fb in 
HCC patients. The results indicated that both the mRNA and protein expression of GnT-IVa were sub-
stantially increased in HCC tissues compared with the corresponding adjacent tissues. Knockdown of 
mgat4a in HepG2 cells revealed that the decrease of NA3Fb was directly related with the gene silencing 
of GnT-IVa. GnT-IV can transfer an N-acetylglucosamine (GlcNAc) group to the core α 1–3 mannose of 
N-glycans, forming a β 1–4 linkage, and can act on biantennary sugar chains and generate triantennary 
sugar chains37. The distinct N-glycan branch catalyzed by GnT-IV is the common substrate for GnT-V, 
with a ß1,4- or ß1,6-linked N-acetylglucosamine residue38. Although GnT-IV and GnT-V (the research 
hot spot of the GnT family) have similar function and are required for the formation of multiantennary, 
complex-type N-glycans, there are few studies on GnT-IV compared with GnT-V.
GnT-IVa has a strong relation with many diseases, including type 2 diabetes39, choriocarcinoma40, 
pancreatic cancer41,and primary colorectal carcinoma42. However, there are few studies investigating 
the relationship between GnT-IVa expression and hepatocarcinoma. Deguchi et al. showed that the 
GnT V-catalyzed N-glycan products did not increase, but a clear increase in the proportion of GnT 
IV products was observed in mouse tumors43. This is in agreement with our results showing that the 
expression of GnT-IVa substantially increased in HCC tissues and the products of the GnT-Iva-catalyzed, 
core-α -1, 6-fucosylated triantennary glycan increased on the cell surface and in the serum of the same 
HCC patients. Further studies showed that GnT-IVa regulatesthe migration and invasion of HCC cells, 
Figure 6. The GnT-IVa is related with cell migration of HepG2. (A) The picture of scratch wound 
migration assay. Healing due to cell migration of HepG2 was observed over a period of 6 h and 48 h 
following scratch wounding. (B) Quantitative data from the cell scratch healing assay is shown. (C) The 
picture of cell migration and invasion using a Transwell assay. (D) Quantitative data of cell migration and 
invasion.
www.nature.com/scientificreports/
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which is similar to Fan’s research44. Mice deficient in GnT-IVa demonstrated that GnT-IVa is essential 
for the production of a complex-type glycan ligand on pancreatic β cells45, which indicated that GnT-IVa 
may play important roles during the process of hepatocarcinoma growth and metastasis. These studies 
demonstrated that the formation of proper antennal complexity on N-glycans is crucial for maintaining 
biological processes in normal contexts34. Our preliminary study of this abnormal glycosylation mech-
anism provided new paths for the research of the carcinogenesis and malignant progression of HCC.
Moreover, we found that M8 was significantly decreased in the tumor group (p < 0.01) compared with 
the adjacent normal tissue group. M8 was increased by approximately 20% in the GnT-IVa knockdown 
HepG2 cell lines by mgat4a-homo-1668. The high-mannose-type N-glycans play an important role in 
allowing only properly folded proteins to pass the quality control system in the endoplasmic reticulum 
and to move to the Golgi apparatus. The N-glycans are subsequently processed by Golgi-resident gly-
cosyltransferases and glycosidases and acquire complex branch structures bearing a variety of glycan 
moieties46. The high mannose M8 is the precursor and intermediate product of N-glycan synthesis. The 
increasing level of NA3Fb and the decreasing level of M8 may be explained by the increased activity of 
GnT-IVa. Most of the M8 was used as a substrate to synthesize NA3Fb, which led to an increased abun-
dance of NA3Fb, and minimal M8 was left during the cell transformation.
In conclusion, the current study revealed the HCC tissue N-glycan profiles and the specific glycans 
on the HCC cell surface: NA2, NA3, M8 and NA3Fb. The change of NA3Fb was not influenced by HBV 
or cirrhosis. NA3Fb can be regarded as a potential drug target for tumor therapy. Furthermore, the 
mechanism study showed that the increase of NA3Fb results from the increased expression of GnT-IVa. 
GnT-IVa regulates cell migration and invasion through NA3Fb and may play important roles in HCC. 
This study provided additional insight and led to a better understanding of the mechanisms of tumor-
igenesis, progression and metastasis of HCC by confirming that altered glycosylation is involved in the 
pathogenesis of malignancies.
Methods
Tissue and serum specimens. The Tumor Hospital of Harbin Medical University provided 88 
pairs of matched adjacent normal and tumor specimens and 61 serum specimens from 88 patients with 
histologically proven primary hepatocarcinoma. 90 age- and gender-matched serum specimens from 
healthy human were used as serum control group. The stage was classified according to the TNM cri-
teria (2002)47. The research was approved by the Ethical Committee of the Tumor Hospital of Harbin 
Medical University, and was in accordance with the ethical standards laid down in the 1964 Declaration 
of Helsinki. The written informed consents of all participating subjects were obtained before commence-
ment of the study.
N-glycome analysis of cell membrane and serum. The N-glycans analysis of cell membrane 
was performed as described previously11. In brief, the ultracentrifugation was used to separate the cell 
membrane fractions. The N-glycans present on the cell membrane proteins were released by PNGase F 
(NEB). Sialic acid was removed with neuraminidase (NEB). The N-glycans were labeled with 8-amino-
1, 3, 6-pyrenetrisulfonic acid (APTS, Invitrogen) and purified with Sephadex G10 (Invitrogen). Finally, 
the samples above were analyzed by ABI3130 Genetic Analyzer (Applied Biosystems). The results were 
analyzed using the GeneMapper 4.0 software (Applied Biosystems). Each N-glycan was numerically 
described by normalizing its height to the sum of the heights of all peaks. Serum N-glycome analysis 
was performed as described previously28. The exoglycosidase digestion was used to analyze the structure 
of N-glycan pool9.
HE Staining. 8 μ m-thick sections of frozen tissues were cut and placed on glass slides. Tissue samples 
were stained with hematoxylin and eosin.
Cell culture and shRNA transfection. The human HepG2 and BEL-7402 cell were obtained from 
ATCC and the Shanghai Institute Cell Bank, respectively. For glycan analysis, cells were detached using a 
cell scraper, washed with PBS, pelleted and frozen at − 80 °C until analysis. GnT-IVa and scrambled shRNA 
were purchased from Ji Ma Company (China). The shRNA sequences targeting mgat4a were showed in 
Supplementary Table S2. The shRNAs were transfected using LipofectamineTM 2000 (Invitrogen, USA) 
and then incubated for 24 h to detect the mRNA and 48 h to analyze the GnT-IVa protein level.
RT-PCR and Western Blot. Methods of RNA extraction and real-time RT-PCR analysis were con-
ducted as previously described48. The primers used in PCR were showed in Supplementary Table S1. 
The total protein was gathered and the GnT-IVa antibodies (Abcam company) and GAPDH (Santa Cruz 
Biotechnology) were used in western blot process. And the band intensity was quantified by arithmetic 
analysis using the software Image Studio.
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The Wound Healing and Transwell. The wound healing and transwell test were conducted as pre-
viously described49. They were used to study the function of the GnT-IVa by comparing the RNA inter-
ference of HCC cell lines and negative control.
Statistical analysis. Data from at least three independent experiments were used to compare between 
groups. All quantitative variables were presented as mean ± SD. Paired and unpaired t-tests were used 
for comparison of the two tissue groups and serum specimens. Student’s t-test was used to determine 
statistical significance for the intergroup comparisons. Statistical analysis was performed with SPSS 10.0 
software.
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